Obstetric aspects of metabolically associated steatotic liver disease
DOI:
https://doi.org/10.15574/PP.2025.2(102).8796Keywords:
metabolically associated steatotic liver disease, pregnancy, childbirth, obstetricsAbstract
Аim - to review the current literature on the frequency, etiopathogenetic factors, diagnosis and treatment of metabolically associated steatotic liver disease (MASLD) in pregnant women to develop criteria for predicting complications of pregnancy and childbirth.
The relevance of the problem of MASLD worldwide in the general population and in pregnant women is shown. Etiopathogenetic factors and risk factors that determine the occurrence of the disease are considered. The effectiveness of methods for diagnosing and treating pregnant women with MASLD is analyzed. Attention is focused on complications caused by MASLD during pregnancy for both the mother and the fetus. The impact of MASLD on the course of pregnancy and childbirth is considered, in particular, the risk of miscarriage, gestosis, premature birth, placental complications, fetal hypoxia, postpartum hemorrhage, and other obstetric problems.
Conclusions. Metabolically associated steatotic liver disease in the modern world has a tendency to increase in the general population, therefore it is a high socio-economic burden and is a global health problem that needs to be addressed by both medical communities and politicians, especially in obstetric practice, because pregnancy against the background of MASLD is characterized by a high risk of complications of both pregnancy and childbirth, leading to impaired condition of mothers, newborns and subsequent development of children, which indicates the need to develop criteria for routine screening of this nosology before conception and during pregnancy to identify a high risk group for the development of MASLD, criteria for timely prediction of complications of pregnancy, childbirth and optimize the tactics of pregnancy, childbirth and the postpartum period, which will lead to a decrease in obstetric and perinatal complications.
The authors declare no conflict of interest.
References
Ajmera VH, Terrault NA, VanWagner LB, Sarkar M, Lewis CE et al. (2019). Longer lactation duration is associated with decreased prevalence of nonalcoholic fatty liver disease in women. J Hepatol. 70(1): 126-132. Epub 2018 Nov 1. https://doi.org/10.1016/j.jhep.2018.09.013; PMid:30392752 PMCid:PMC6599460
Ajmera VH, Gunderson EP, VanWagner LB, Lewis CE, Carr JJ, Terrault NA (2016). Gestational diabetes mellitus is strongly associated with non-alcoholic fatty liver disease. Am J Gastroenterol. 111(5): 658-664. Epub 2016 Mar 22. https://doi.org/10.1038/ajg.2016.57; PMid:27002796 PMCid:PMC4860097
Ammon FJ, Kohlhaas A, Elshaarawy O, Mueller J, Bruckner T, Sohn C, Fluhr G et al. (2018). Liver stiffness reversibly increases during pregnancy and independently predicts preeclampsia. World J Gastroenterol. 24(38): 4393-4402. https://doi.org/10.3748/wjg.v24.i38.4393; PMid:30344423 PMCid:PMC6189842
Armistead B, Johnson E, VanderKamp R, Kula-Eversole E, Kadam L et al. (2020). Placental regulation of energy homeostasis during human pregnancy. Endocrinology. 161(7): bqaa076. https://doi.org/10.1210/endocr/bqaa076; PMid:32417921 PMCid:PMC10061055
Ayonrinde OT, Oddy WH, Adams LA, Mori TA, Beilin LJ et al. (2017). Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. J Hepatol. 67(3): 568-576. Epub 2017 Jun 12. https://doi.org/10.1016/j.jhep.2017.03.029; PMid:28619255
Bahnii LV, Heriak SM, Bahnii NI. (2020). Patohenetychni aspekty formuvannia akusherskykh uskladnen u vahitnykh iz nealkoholnoiu zhyrovoiu khvoroboiu pechinky pry nadlyshkovii masi tila. Zbirnyk naukovykh prats asotsiatsii akusher-hinekolohiv Ukrainy «Aktualni pytannia pediatrii, akusherstva ta hinekolohii. 2: 37-44. https://doi.org/10.35278/2664-0767.1(47).2021.242659
Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F et al. (2016). Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 31: 936-944. https://doi.org/10.1111/jgh.13264; PMid:26667191
Benyuk SV. (2015). Intrahepatic cholestasis of pregnancy. The consequences for the fetus and newborn. Health of woman. 2(98): 62-64. https://doi.org/10.15574/HW.2015.98.62
Bichevskaya RG. (2021). Osoblyvosti imunopatohenezu ta imunokorektsii u zhinok z nevynoshuvanniam vahitnosti na foni khronichnykh zakhvoriuvan hepatobiliarnoi systemy. Dysertatsiia. Odesa: 40.
Bichevska RH, Loskutova IV. (2018). Vyraznist fibrozu pechinky u zhinok zi zvychnym nevynoshuvanniam vahitnosti ta khronichnymy zakhvoriuvanniamy hepatobiliarnoi systemy. Danish Scientific Journal. 8: 39-44.
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. (2013). The burden of liver disease in Europe: a review of available epidemiological data. J. Hepatol. 58(3): 593-608. https://doi.org/10.1016/j.jhep.2012.12.005; PMid:23419824
Bril F, Barb D, Portillo-Sanchez P, Biernacki D, Lomonaco R, Suman A et al. (2017). Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology. 65(4): 1132-1144. Epub 2017 Feb 25. https://doi.org/10.1002/hep.28985; PMid:27981615
CDC. (2024). Weight Gain During Pregnancy. Updated May 15, 2024. URL: https://www.cdc.gov/maternal-infant-health/pregnancyweight/index.html.
Cemortan M. (2023). Diagnosis and course of pregnancy and childbirth in women with intrahepatic cholestasis of pregnancy: Summary of Ph. D. Thesis in Medical Sciences: 321.15. Obstetrics and Gynecology. URL: https://repository.usmf.md/handle/20.500.12710/25315.
Chagas LA, Torloni MR, Sanchez VHS, Pititto BA, Dualib PM, Mattar R. (2023, Oct). Dietary intake of pregnant women with non-alcoholic fatty liver disease: a case-control study. Clin Nutr ESPEN. 57: 630-636. Epub 2023 Aug 19. https://doi.org/10.1016/j.clnesp.2023.08.018; PMid:37739716
Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. (2020). Harnessing muscle-liver crosstalk to treat nonalcoholic steatohepatitis. Front Endocrinol. 11: 592373. https://doi.org/10.3389/fendo.2020.592373; PMid:33424768 PMCid:PMC7786290
Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al. (2018). The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 67(1): 328-357. Epub 2017 Sep 29. https://doi.org/10.1002/hep.29367; PMid:28714183
Cho Y, Chang Y, Ryu S, Kim C, Wild SH, Byrne CD. (2023). History of gestational diabetes and incident nonalcoholic fatty liver disease: the kangbuk samsung health study. Am J Gastroenterol. 118(11): 1980-1988. Epub 2023 Mar 20. https://doi.org/10.14309/ajg.0000000000002250; PMid:36940424
Cohen CC, Perng W, Sauder KA, Shapiro ALB, Starling AP, Friedman C et al. (2023). Maternal diet quality during pregnancy and offspring hepatic fat in early childhood: the healthy start study. J Nutr. 153(4): 1122-1132. Epub 2023 Feb 14. https://doi.org/10.1016/j.tjnut.2023.01.039; PMid:36796482 PMCid:PMC10196613
Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D et al. (2017). Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omicsbased approach. Hepatology. 65(2): 451-464. Epub 2016 Jun 2. https://doi.org/10.1002/hep.28572; PMid:27028797
De Lorenzo А, Soldati L, Sarlo F, Calvani M. (2016). New obesity classification criteria as a tool for bariatric surgery indication. World J. Gastroenterol. 22(2): 681-703. https://doi.org/10.3748/wjg.v22.i2.681; PMid:26811617 PMCid:PMC4716069
Dixon PH, Wadsworth CA, Chambers J et al. (2014). A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J gastroenterol. 109: 76-84. https://doi.org/10.1038/ajg.2013.406; PMid:24366234 PMCid:PMC3887577
Dowman JK, Tomlinson JW, Newsome PN. (2010). Pathogenesis of non-alcoholic fatty liver disease. QJM. 103: 71-83. Epub 2009 Nov 13. https://doi.org/10.1093/qjmed/hcp158; PMid:19914930 PMCid:PMC2810391
EASL, EASD, EASO. (2024, Sep). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD). Journal of Hepatology. 81: 492-542. https://doi.org/10.1016/j.jhep.2024.04.031; PMid:38851997
Ekom Nsed EN, Boichuk OH, Heryak SM, Nikitina IM, Khmil SV, Myhovych VV. (2021). Condition of fetures and newborns from women with infertility treated with assisted reproductive technologies and with concomitant intrahepatic cholestasis. URL: https://essuir.sumdu.edu.ua/handle/123456789/87734. https://doi.org/10.36740/WLek202107127; PMid:34459776
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. (2018). Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 67(1): 123-133. https://doi.org/10.1002/hep.29466; PMid:28802062 PMCid:PMC5767767
European Association for the Study of the Liver, et al. (2024). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Obes Facts. 17(4): 374-444. https://doi.org/10.1159/000539371; PMid:38852583 PMCid:PMC11299976
Falzarano C, Lofton T, Osei-Ntansah A, Oliver T, Southward T et al. (2022). Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome. J Clin Endocrinol Metab. 107(1): 258-272. https://doi.org/10.1210/clinem/dgab658; PMid:34491336
Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. (2016). Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 65(8): 1017-1025. Epub 2016 Jan 29. https://doi.org/10.1016/j.metabol.2016.01.012; PMid:26997539
Foghsgaard S, Andreasen C, Vedtofte L, Andersen ES, Bahne E, Strandberg C et al. (2017). Nonalcoholic fatty liver disease is prevalent in women with prior gestational diabetes mellitus and independently associated with insulin resistance and waist circumference. Diabetes Care. 40(1): 109-116. Epub 2016 Nov 3. https://doi.org/10.2337/dc16-1017; PMid:27810989
Forbes JD, Azad MB, Vehling L, Tun HM, Konya TB, Guttman DS et al. (2018). Association of exposure to formula in the hospital and subsequent infant feeding practices with gut microbiota and risk of overweight in the first year of life. JAMA Pediatr. 172(7): e181161. https://doi.org/10.1001/jamapediatrics.2018.1161; PMid:29868719 PMCid:PMC6137517
Goldner D, Lavine JE. (2020). Nonalcoholic fatty liver disease in children: unique considerations and challenges. Gastroenterology. 158(7): 1967-1983. https://doi.org/10.1053/j.gastro.2020.01.048; PMid:32201176
Gotteland M, Magne F. (2017). Alterations in human milk leptin and insulin are associated with early changes in the infant intestinal microbiome. Am J Clin Nutr. 105(1): 234. https://doi.org/10.3945/ajcn.116.140129; PMid:28049664 PMCid:PMC5183729
Gross A, Lange M, Rosenbluth E, Carroll C, Sperling R, Juliano C et al. (2023). Evaluation of 2-year outcomes in infants born to mothers with and without NAFLD in pregnancy. Eur J Pediatr. 182(8): 3765-3774. Epub 2023 Jun 13. https://doi.org/10.1007/s00431-023-05044-7; PMid:37310499 PMCid:PMC12166767
Hagstrom H, Höijer J, Ludvigsson JF, Bottai M, Ekbom A, Hultcrantz R et al. (2016). Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease. Liver Int. 36(2): 268-274. https://doi.org/10.1111/liv.12902; PMid:26114995
Hagstrom H, Simon TG, Roelstraete B, Stephansson O, Söderling J, Ludvigsson JF. (2021). Maternal obesity increases the risk and severity of NAFLD in offspring. J Hepatol. 75(5): 1042-1048. Epub 2021 Jul 18. https://doi.org/10.1016/j.jhep.2021.06.045; PMid:34289397
Hagstrom H, Vessby J, Ekstedt M, Shang Y. (2024). 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 80(2): e76-e77. Epub 2023 Sep 9. https://doi.org/10.1016/j.jhep.2023.08.026; PMid:37678723
Jung YM, Lee SM, Wi W, Oh MJ, Park JS et al. (2024). Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunctionassociated steatotic liver disease in postpartum women: a nationwide study. JHEP Rep. 6(4): 101033. https://doi.org/10.1016/j.jhepr.2024.101033; PMid:38524668 PMCid:PMC10960121
Kahn CR, Wang G, Lee KY. (2019). Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 129: 3990-4000. https://doi.org/10.1172/JCI129187; PMid:31573548 PMCid:PMC6763230
Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. (2024). Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 79(5): 1212-1219. Epub 2023 Nov 9. https://doi.org/10.1097/HEP.0000000000000670; PMid:38445559
Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME et al. (2021). Preparing for the NASH epidemic: a call to action. Gastroenterology. 161(3): 1030-1042.е8 Epub 2021 Jul 26. https://doi.org/10.1053/j.gastro.2021.04.074
Karachaliou GS, Suzuki A, Patel VA, Bastian LA, Diehl AM, Abdelmalek MF et al. (2024). Longer breastfeeding duration is associated with decreased risk of hepatic fibrosis among young women with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 22(2): 413-415.e3. Epub 2023 Jun 10. https://doi.org/10.1016/j.cgh.2023.05.027; PMid:37302447
Koralegedara IS, Warnasekara JN, Dayaratne KG, De Silva FN, Premadasa JK, Agampodi SB. (2022). Non-alcoholic fatty liver disease (NAFLD): a significant predictor of gestational diabetes mellitus (GDM) and early pregnancy miscarriages-prospective study in Rajarata Pregnancy Cohort (RaPCo). BMJ Open Gastroenterol. 9(1): e000831. https://doi.org/10.1136/bmjgast-2021-000831; PMid:35193889 PMCid:PMC8867246
Kumarendran B, O'Reilly MW, Manolopoulos KN, Toulis KA, Gokhale KM, Sitch AJ et al. (2018). Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database. PLoS Med. 15: e1002542. https://doi.org/10.1371/journal.pmed.1002542; PMid:29590099 PMCid:PMC5873722
Lao TT. (2020, Oct). Implications of abnormal liver function in pregnancy and non-alcoholic fatty liver disease. Best Pract Res Clin Obstet Gynaecol. 68: 2-11. Epub 2020 Mar 7. https://doi.org/10.1016/j.bpobgyn.2020.02.011; PMid:32312689
Loomba R, Friedman SL, Shulman GI. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 184: 2537-2564. https://doi.org/10.1016/j.cell.2021.04.015; PMid:33989548 PMCid:PMC12168897
Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E et al. (2024). Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 391(4): 299-310. Epub 2024 Jun 8. https://doi.org/10.1056/NEJMoa2401943; PMid:38856224
Lund-Blix NA, Dydensborg Sander S, Størdal K, Nybo Andersen AM, Rønningen KS, Joner G et al. (2017). Infant feeding and risk of type 1 diabetes in two large Scandinavian birth cohorts. Diabetes Care. 40(7): 920-927. Epub 2017 May 9. https://doi.org/10.2337/dc17-0016; PMid:28487451 PMCid:PMC5481976
Maldonado SS, Grab J, Wang CW, Huddleston H, Cedars M, Sarkar M. (2022). Polycystic ovary syndrome is associated with nonalcoholic steatohepatitis in women of reproductive age. Hepatol Commun. 6(10): 2634-2639. Epub 2022 Jul 21. https://doi.org/10.1002/hep4.2039; PMid:35861548 PMCid:PMC9512460
Murphy K, Curley D, O'Callaghan TF, O'Shea CA, Dempsey EM, O'Toole PW et al. (2017). The composition of human milk and infant faecal microbiota over the first three months of life: a pilot study. Sci Rep. 7: 40597. https://doi.org/10.1038/srep40597; PMid:28094284 PMCid:PMC5240090
Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Østergaard L, Vanni D et al. (2024). Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE Trial. Aliment Pharmacol Ther. 60(11-12): 1525-1533. Epub 2024 Oct 16. https://doi.org/10.1111/apt.18331; PMid:39412509 PMCid:PMC11599791
Organization of Teratology Information Specialists. (2024). Tirzepatide (Mounjaro, Zepbound). Updated May 1, 2024. URL: https:// mothertobaby.org/fact-sheets/tirzepatide/.
Ozempic. (2025). Package insert. Novo Dordisk.
Polishchuk IP, Henyk NI, Zhukuliak OM, Bihun RV, Perkhulyn OM. (2024, Jun). Funktsionalnyi stan pechinky u vahitnykh z hipotonichnoiu dyskineziieiu zhovchnykh shliakhiv. In The 25th International scientific and practical conference "Universities and schools: methods of distance learning" (June 25-28, 2024) Boston, USA. International Science Group: 220. (s. 116).
Рrуlutska AB, Martynova LI, Kisilenko ОL, Tsema TА, Govsіeіev DО. (2025). Obstetric aspects of diseases of the hepatobiliary system. Ukrainian Journal of Perinatology and Pediatrics. 1(101): 111-116. https://doi.org/10.15574/PP.2025.1(101).111116
Qian Y, Zhang Y, Fan X, Yan H, Li X, Fan Y et al. (2023). Nonalcoholic fatty liver disease and adverse pregnancy outcomes in women with normal prepregnant weight. J Clin Endocrinol Metab. 108(2): 463-471. https://doi.org/10.1210/clinem/dgac567; PMid:36181486
Rezdiffra. (2024). Package insert. Madrigal Pharmaceuticals.
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al. (2023, May 1). AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 77(5): 1797-1835. Epub 2023 Mar 17. https://doi.org/10.1097/HEP.0000000000000323; PMid:36727674 PMCid:PMC10735173
Rinella ME. (2015). Nonalcoholic fatty liver disease: a systematic review. 313(22): 2263-2273. https://doi.org/10.1001/jama.2015.5370; PMid:26057287
Rumbold A, Ota E, Hori H, Miyazaki C, Crowther CA. (2015). Vitamin E supplementation in pregnancy. Cochrane Database Syst Rev. 2015(9): CD004069. https://doi.org/10.1002/14651858.CD004069.pub3; PMid:26343254 PMCid:PMC8406700
Sanders FWB, Acharjee A, Walker C, Marney L, Roberts LD, Imamura F et al. (2018). Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption. Genome Biol. 19: 79. https://doi.org/10.1186/s13059-018-1439-8; PMid:29925420 PMCid:PMC6009819
Sanli E, Kabaran S. (2019). Maternal obesity, maternal overnutrition and fetal programming: effects of epigenetic mechanisms on the development of metabolic disorders. Curr Genomics. 20(6): 419-427. https://doi.org/10.2174/1389202920666191030092225; PMid:32476999 PMCid:PMC7235386
Sarkar M, Brady CW, Fleckenstein J, Forde KA, Khungar V, Molleston JP et al. (2021). Reproductive health and liver disease: practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 73(1): 318-365. Epub 2021 Jan 3. https://doi.org/10.1002/hep.31559; PMid:32946672
Sarkar M, Kushner T. (2025). Metabolic dysfunction-associated steatotic liver disease and pregnancy. J Clin Invest. 135(10): e186426. https://doi.org/10.1172/JCI186426; PMid:40371643 PMCid:PMC12077888
Sarkar M, Terrault N, Chan W, Cedars MI, Huddleston HG, Duwaerts CC et al. (2020). Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int. 40(2): 355-359. Epub 2019 Nov 12. https://doi.org/10.1111/liv.14279; PMid:31627243 PMCid:PMC6980925
Shen C, Hu W, Wu T, Wang G, Qiao L, Gao T. (2024). Analysis of changes in platelet parameters and inflammatory markers in intrahepatic cholestasis of pregnancy before disease development. American Journal of Translational Research. 16(12): 7448. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11733396/. https://doi.org/10.62347/OWXV5949; PMid:39822511 PMCid:PMC11733396
Shumacher JD, Guo GL. (2015). Mechanustic review of drug-induced steatohepatitits. Toxicol. Appl. Pharmacol. 289(1): 40-47. https://doi.org/10.1016/j.taap.2015.08.022; PMid:26344000 PMCid:PMC4628855
Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C et al. (2019). Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 17(9): 1877-1885.e5. Epub 2019 Jan 4. https://doi.org/10.1016/j.cgh.2018.12.031; PMid:30616027 PMCid:PMC6609497
Soresi M, Noto D, Cefalu AB et al. (2013). Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Acta Diabetol. 50(2): 241-249. Epub 2012 Jun 9. https://doi.org/10.1007/s00592-012-0406-1; PMid:22684314
Stenberg Ribeiro M, Hagström H, Stål P, Ajne G. (2019). Transient liver elastography in normal pregnancy - a longitudinal cohort study. Scand J Gastroenterol. 54(6): 761-765. Epub 2019 Jul 5. https://doi.org/10.1080/00365521.2019.1629007; PMid:31272248
Terrault NA, Williamson C. (2022, Jul). Pregnancy-Associated Liver Diseases. Gastroenterology. 163(1): 97-117.e1. Epub 2022 Mar 8. doi: 10.1053/j.gastro.2022.01.060. https://doi.org/10.1053/j.gastro.2022.01.060; PMid:35276220
Unalp-Arida A, Ruhl CE. (2017). Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 66(1): 84-95. https://doi.org/10.1002/hep.29113; PMid:28195363 PMCid:PMC7005915
Wesolowski SR, Kasmi KC, Jonscher KR, Friedman JE. (2017). Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol. 14(2): 81-96. Epub 2016 Oct 26. https://doi.org/10.1038/nrgastro.2016.160; PMid:27780972 PMCid:PMC5725959
Wu J, Yao XY, Shi RX, Liu SF, Wang XY. (2018). A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health. 15: 77. https://doi.org/10.1186/s12978-018-0519-2; PMid:29747678 PMCid:PMC5946415
Yamakawa M, Yorifuji T, Inoue S, Kato T, Doi H. (2013). Breastfeeding and obesity among schoolchildren: a nationwide longitudinal survey in Japan. JAMA Pediatr. 167(10): 919-925. https://doi.org/10.1001/jamapediatrics.2013.2230; PMid:23939787
Zeng J, Shen F, Zou ZY, Yang RX, Jin Q, Yang J et al. (2022). Association of maternal obesity and gestational diabetes mellitus with overweight/ obesity and fatty liver risk in offspring. World J Gastroenterol. 28(16): 1681-1691. https://doi.org/10.3748/wjg.v28.i16.1681; PMid:35581961 PMCid:PMC9048784
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ukrainian Journal of Perinatology and Pediatrics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “Ukrainian Journal of Perinatology and Pediatrics” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license(СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
